Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world orelabrutinib in treatment-naïve CLL
ChiCTR2600128018Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of orelabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Time to Next Treatment (TTNT). Started Jul 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2600128018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128018.